2023-05-08 16:03:02 ET
- Y-mAbs Therapeutics press release ( NASDAQ: YMAB ): Q1 GAAP EPS of -$0.15 beats by $0.17 .
- Revenue of $20.25M (+93.0% Y/Y) beats by $4.7M .
- Financial Guidance
- We are updating our full-year 2023 financial guidance, which now reflects:
- Anticipated DANYELZA® net product revenues now expected to be $80-85 million (previously $60-65 million);
- Anticipated operating expenses continues to be expected to be $115-120 million;
- Anticipated total annual cash burn now expected to be $40-50 million (previously $50-55 million); and
- Cash and cash equivalents anticipated to support operations as currently planned into the first quarter of 2026.
For further details see:
Y-mAbs Therapeutics GAAP EPS of -$0.15 beats by $0.17, revenue of $20.25M beats by $4.7M